AMRI Hires Director of In Vitro Biology in Singapore

30-Apr-2012 - Singapore

AMRI  announced a key addition to the management team at its Singapore location. Saravanakumar Dhakshinamoorthy, Ph.D. joins AMRI's Singapore site as Director of In Vitro Biology, reporting to Takeshi Yura, Ph.D., Senior Director, AMRI Singapore. As the leader of AMRI's biology resources and staff in Singapore, Dr. Dhakshinamoorthy and his team will be working closely with on-site colleagues supporting customer projects as well as in collaboration with AMRI's U.S.-based biology and DMPK teams.

Dr. Dhakshinamoorthy comes to AMRI after seven years with Aurigene, a discovery services company in Bangalore, India. He previously worked in Singapore with the Institute of Molecular and Cell Biology. He brings more than 20 years of postgraduate experience in academic and industrial settings to AMRI.

Dr. Dhakshinamoorthy received his Ph.D. in Biotechnology in 1998, from the Centre for Biotechnology, Anna University, Chennai, India. His Postdoctoral research was conducted at Baylor College of Medicine in Houston, Texas.

Other news from the department people

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

Last viewed contents

Action Pharma reports positive results in a proof of concept phase IB study in obese human volunteers treated with AP1030

Amira Pharmaceuticals Announces Completion of Phase 1 Clinical Study for AM152, A Novel LPA1 Receptor Antagonist - Company Anticipates Initiating Phase 2a Studies by Early 2012

Elbion AG appoints Dr. Thomas Taapken as Chief Financial Officer and Member of the Executive Board

Galapagos and CHDI Foundation, Inc. enter new five-year collaboration for Huntington's disease therapeutics

Glaxosmithkline and Elbion to Collaborate on Development and Commercialisation of a new DE IV Inhibitor

RIKEN: Discovery of DNA Silencing Mechanism Reveals How Plants Protect Their Genome

Novasep invests EUR 30 million to build world's largest chromatography plant for the pharmaceutical industry - New plant on its Mourenx, France site to produce a large volume commercial API

Prosensa Announces Progress on Exon Skipping Compounds for the Treatment of Duchenne Muscular Dystrophy - £10m in milestone payments received from GlaxoSmithKline

KINAXO Biotechnologies receives 1 million EUR funding to quantify drug interactions with cellular protein targets

Effectiveness of drug to improve natriuretic peptide levels for chronic heart failure

Dyax Corp. and Cubist Pharmaceuticals, Inc. Sign Development and Commercialization Agreement for DX-88 Surgical Indications

Prosensa receives rare disease 'Company Award' from EURORDIS